Stock analysis, price data, and AI-powered insights for Bio-Techne (TECH).
Bio-Techne operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for TECH.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). TECH Stock Intelligence Report. [stoxpulse.com/stocks/tech]
Disclaimer: The information on this page about Bio-Techne (TECH) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Bio-Techne.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings miss
Mar 31
Crouse bought 600 shares
Jun 2
Crouse sold 216 shares
Jun 2
Is Bio-Techne Corporation (TECH) A Good Stock To B...
1d ago
Intel upgraded, Reddit initiated: Wall Street's to...
Apr 21
StoxPulse AI results for TECH: Pulse Score 50/100. Primary sentiment trends from 6 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$8.45B
P/E Ratio
110.4
EPS
$0.24
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+4.1%
Sep 25
-2.0%
Dec 25
+4.0%
Mar 26
-3.3%
Beat estimates 2 of 4 quarters (50%)
Sector
Healthcare
Industry
Life Sciences Tools & Services
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
2026-06-04
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
2026-05-12
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
2026-05-07
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
2026-05-07
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
2026-05-07
Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now?
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
1 S&P 500 Stock with Impressive Fundamentals and 2 We Brush Off
Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
3 Reasons TECH is Risky and 1 Stock to Buy Instead